Skip to Content
Last Updated: 12/29/15

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-095 (UH2/UH3)

Posted date: January 21, 2015; Expiration date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is a phased initiative to improve the development of molecular diagnostics for use in NCI-supported clinical trials in cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-16-056 (U10)

Posted Date: December 10, 2015; Expiration Date: October 7, 2017
Letter of Intent due dates: 30 days prior to the application due date
Application due dates: February 29, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that has essentially completed analytical validation in human samples and whose importance is well justified for development into a clinical assay. Revisions may support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Projects proposed for this FOA require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff.

CDP contacts: Dr. Magdalena Thurin thurinm@mail.nih.gov for assays involving immunological diagnostics and non-companion diagnostics for treatment trials and Dr. Tracy Lively livelyt@mail.nih for response, safety, resistance and risk stratification markers for treatment trials.

Cancer Detection, Diagnosis, and Treatment Technologies for Global Health: RFA-CA-15-001 (UH2/UH3)

Release/Posted date: November 24, 2014; Expiration date: March 7, 2015 (Pending Renewal)
Application due date: March 6, 2015.

This Funding Opportunity Announcement (FOA) is an initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-096 (UH3)

Posted date: January 21, 2015; Expiration Date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) PAR-13-169

Release/Posted date: April 5, 2013; Expiration date: May 8, 2016
Application receipt dates: February 5, June 5, October 5

This FOA encourages applications from research partnerships formed by academic and industrial investigators. The partnerships should establish an inter-disciplinary research team to work in strategic alliance to develop and translate in vivo imaging systems or support reference methods required to validate in vivo imaging systems on a targeted cancer problem.

Contact: Dr. Houston Baker, CIP, 240-276-5908, bakerhou@mail.nih.gov;
Dr. James A. Deye, 240-276-5690, deyej@mail.nih.gov or
Mr. Miguel R. Ossandon, 240-276-5680, ossandom@mail.nih.gov

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PA-12-284 (R21)

Release/Posted Date: October 14, 2009; Expiration date: January 8, 2016
Application Receipt Dates: February 16, June 16, October 16

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

Bioengineering Research Grants [BRG]: PAR-13-137 (R01)

Release/Posted Date: October 14, 2009; Expiration date: May 8, 2016
Application Receipt Dates: February 5, June 5, October 5

The BRGs support multi-disciplinary research performed in in a single laboratory or by multiple organizations. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Bioengineering Research Partnerships [BRP]: PAR-14-092 (R01)

Release/Posted Date: February 6, 2014; Expiration date: January 8, 2016
Application Receipt Dates: May 20, September 18

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

The NCI Innovative Molecular Analysis Technologies (IMAT) Program (http://innovation.cancer.gov/)

Release/Posted date: January 8, 2015; Expiration date: September 23, 2015 (Pending Renewal)
Application due date(s): March 17, 2015; June 17, 2015; September 22, 2015

IMAT supports the development of next-generation analytical methodologies and tools that have the potential to revolutionize cancer research, prevention, detection, diagnostics and treatment. The IMAT program funds research in four areas:

Innovative Molecular AnalysisTechnology Development for Cancer Research: RFA-CA-15-002 (R21)

This FOA solicits grant applications proposing exploratory research projects focused on the inception and development of early-stage, highly innovative, molecular and/or cellular analysis technologies with transformative potential not yet explored in cancer-relevant use.

CDP contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov

Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research: RFA-CA-15-003 (R33)

The program funds research projects on the advanced development of emerging molecular and cellular analysis technologies and validation in an appropriate cancer-relevant biological system.

CDP contact: Dr. Brian Sorg, 240-276-5712, sorgbs@mail.nih.gov

Innovative Technologies forCancer-Relevant Biospecimen Science: RFA-CA-15-004 (R21)

The program funds exploratory research projects on the inception and early-stage development of technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens.

CDP contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov

Validation and Advanced Development of Emerging Technologies for Biospecimen Science: RFA-CA-15-005 (R33)

The program funds research projects on the advanced development and validation of technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens.

CDP contact: Dr. Rodrigo Chuaqui, 240-276-5910, chuaquir@mail.nih.gov

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services